Diligence memo · auto-generated · as of July 3, 2026
Ensysce Biosciences, Inc.
Ensysce Biosciences, Inc. looks under-valued against its niche peers and is active on financing cadence.
Businessfiled
Ensysce Biosciences, Inc. operates in Biotech / Pharma, based in LA JOLLA.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Ensysce Biosciences, Inc. has raised $25M in disclosed capital across 7 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $5.3M on 2021-09-24.
Most recent recorded round closed around 2025-04-23.
Valuation (modeled)modeled
Provath models Ensysce Biosciences, Inc. at approximately $7.9M (range $2.5M–$14M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.46× the median modeled value of Series A Biotech / Pharma companies in 2025–2027 (16 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 7 months.
Last raise 14 mo ago; this sector typically re-raises about every 15 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 2.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 80% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 31% of those peers.
Closest niche peers: Evio Pharmacy Solutions, LLC, Ruby Bio, Inc., Intelligent Bio Solutions Inc., Barnwell Bio, Inc., Arkea Bio Corp..
Peoplefiled
9 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.